Omnicell (NASDAQ:OMCL) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Omnicell (NASDAQ:OMCL) from a hold rating to a buy rating in a research report released on Monday morning.

Separately, Benchmark reissued a buy rating and set a $38.00 price target on shares of Omnicell in a report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Omnicell has an average rating of Hold and an average price target of $42.20.

Omnicell Trading Up 4.5 %

NASDAQ OMCL opened at $26.77 on Monday. Omnicell has a 1 year low of $25.12 and a 1 year high of $75.07. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. The company has a market capitalization of $1.23 billion, a PE ratio of -58.20, a P/E/G ratio of 93.23 and a beta of 0.80. The company has a fifty day moving average of $29.25 and a 200 day moving average of $29.84.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.17. The business had revenue of $246.15 million during the quarter, compared to analysts’ expectations of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. Research analysts forecast that Omnicell will post 0.2 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EntryPoint Capital LLC increased its stake in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Omnicell in the third quarter valued at approximately $78,000. CWM LLC grew its holdings in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the period. Benjamin Edwards Inc. increased its holdings in shares of Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares during the last quarter. Finally, Strs Ohio raised its position in Omnicell by 28.2% in the fourth quarter. Strs Ohio now owns 5,000 shares of the company’s stock valued at $188,000 after purchasing an additional 1,100 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.